Survey finds variability in MS treatment preferences among individual patients, and among stakeholder groups – Yahoo Finance

WESTPORT, CT--(Marketwired - January 31, 2017) - Real Endpoints, LLC (RE), a data and analytics firm focusing on assessing and quantifying pharmaceutical value, has just completed an extensive literature review and survey to tease out how different stakeholder groups assess the value of current multiple sclerosis (MS) therapies.1

Key findings of the literature review and survey are two-fold:

Conclusions

Preliminary results of the survey and literature review indicate that population-level judgments of value may not capture the variability in preferences and treatment effect among individual MS patients, payers and physicians (further research should be done to confirm these findings). Additionally, potential disparity may exist between judgments of value used at the payer level to determine coverage of MS treatments, and what MS patients would define as valuable in their own treatment decision-making.

This variability should be taken into account in healthcare decision-making, on the payer, provider and patient level. Furthermore, any tool, such as a value framework, used to quantify the value of an MS treatment should transparently define the differences in preferences and treatment goals.

Key Findings

Background & Methodology

A team of trained academic and non-academic clinicians and researchers reviewed over 300 research articles from scientific literature around disease heterogeneity, patient preference, and disease economics in multiple sclerosis.

To solicit response on stakeholder preferences in MS treatment 90 individuals were surveyed including thirty people diagnosed with MS, 30 payers, and 30 neurologists who treat MS.

The survey was based upon RE's RxScorecard drug-value assessment framework, a fully transparent, evidence-based tool that comparatively "scores" drugs that treat a particular disease.

Detailed documentation will be released in the near future, including full synthesis and reporting of collected survey data and literature review, description of methodology, and incorporation of findings into RxScorecard and potentially other frameworks to help transparently define value from the points of view of multiple stakeholders, including patients, physicians and payers.

About Real Endpoints

Real Endpoints (RE) is a healthcare information and analytics company that prepares healthcare providers, payers and pharmaceutical companies for the value-based healthcare economy. For information contact Viviana Ramos at vramos@realendpoints.com.

Learn more at http://www.realendpoints.com

1 The project was funded by the Pharmaceutical Research and Manufacturers of America (PhRMA).

Continued here:
Survey finds variability in MS treatment preferences among individual patients, and among stakeholder groups - Yahoo Finance